JPWO2021033247A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021033247A5 JPWO2021033247A5 JP2021541368A JP2021541368A JPWO2021033247A5 JP WO2021033247 A5 JPWO2021033247 A5 JP WO2021033247A5 JP 2021541368 A JP2021541368 A JP 2021541368A JP 2021541368 A JP2021541368 A JP 2021541368A JP WO2021033247 A5 JPWO2021033247 A5 JP WO2021033247A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- macrophages
- cell population
- composition according
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 13
- 210000004322 M2 macrophage Anatomy 0.000 claims description 7
- 210000005087 mononuclear cell Anatomy 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 4
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/032322 WO2021033247A1 (ja) | 2019-08-19 | 2019-08-19 | 細胞含有医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021033247A1 JPWO2021033247A1 (cg-RX-API-DMAC7.html) | 2021-02-25 |
| JPWO2021033247A5 true JPWO2021033247A5 (cg-RX-API-DMAC7.html) | 2022-08-26 |
| JP7500083B2 JP7500083B2 (ja) | 2024-06-17 |
Family
ID=74659865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541368A Active JP7500083B2 (ja) | 2019-08-19 | 2019-08-19 | 細胞含有医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12460182B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7500083B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102791419B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021033247A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014027474A1 (ja) | 2012-08-17 | 2014-02-20 | 株式会社Clio | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
| WO2014051154A1 (ja) | 2012-09-28 | 2014-04-03 | 公益財団法人先端医療振興財団 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
| AU2015297347B2 (en) | 2014-08-01 | 2021-05-27 | PuREC Co., Ltd | Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method |
| US20160287638A1 (en) | 2015-04-02 | 2016-10-06 | Stemedica Cell Technologies, Inc. | Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease |
| EP3297615A1 (en) * | 2015-05-20 | 2018-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for modulation polarization and activation of macrophages |
| EP3299453B1 (en) * | 2016-09-23 | 2019-05-08 | Xcell Medical Solutions, S.L. | Cell therapy with polarized macrophages for tissue regeneration |
-
2019
- 2019-08-19 US US17/612,441 patent/US12460182B2/en active Active
- 2019-08-19 WO PCT/JP2019/032322 patent/WO2021033247A1/ja not_active Ceased
- 2019-08-19 JP JP2021541368A patent/JP7500083B2/ja active Active
- 2019-08-19 KR KR1020217037758A patent/KR102791419B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarsenova et al. | Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells | |
| He et al. | miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling | |
| Ionescu et al. | Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action | |
| Liu et al. | Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study | |
| Pistoia et al. | Mesenchymal stromal cells and autoimmunity | |
| Li et al. | Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia | |
| Godoy et al. | Clinical translation of mesenchymal stromal cell therapy for graft versus host disease | |
| Samper et al. | Cardiac cell therapy: boosting mesenchymal stem cells effects | |
| JP2020089373A (ja) | 幹細胞培養培地及び細胞生存を増強する方法 | |
| Budgude et al. | Mesenchymal stromal cell‐derived extracellular vesicles as cell‐free biologics for the ex vivo expansion of hematopoietic stem cells | |
| ES3036762T3 (en) | A modulatable switch for selection of donor modified cells | |
| KR20150020113A (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| Chen et al. | Recent advances in the role of mesenchymal stem cells as modulators in autoinflammatory diseases | |
| Vandermeulen et al. | Rationale for the potential use of mesenchymal stromal cells in liver transplantation | |
| CA3115291A1 (en) | Methods for the expansion of mesenchymal stromal cells | |
| Silva et al. | Granulocyte-colony stimulating factor-overexpressing mesenchymal stem cells exhibit enhanced immunomodulatory actions through the recruitment of suppressor cells in experimental chagas disease cardiomyopathy | |
| Ringdén et al. | Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease | |
| Hamzic et al. | Interleukin-6 primarily produced by non-hematopoietic cells mediates the lipopolysaccharide-induced febrile response | |
| Wang et al. | Allogeneic stem cell transplantation combined with transfusion of mesenchymal stem cells in primary myelofibrosis: a multicenter retrospective study | |
| Suresh et al. | Exploring MSC and HSPC interactions: new frontiers in hematopoiesis and transplant medicine | |
| Sadeghi et al. | Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo | |
| Zhang et al. | Research progress on mesenchymal stem cells and their exosomes in systemic sclerosis | |
| Ringdén et al. | Successful reversal of acute lung injury using placenta-derived decidual stromal cells | |
| US20220331359A1 (en) | Purified double negative t cell and preparation and use thereof | |
| Han et al. | The use of normal stem cells and cancer stem cells for potential anti-cancer therapeutic strategy |